0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Metastatic Cutaneous Apocrine Adenocarcinoma Treated With a Combination of Pertuzumab-Based Targeted Therapy and Taxane Chemotherapy A Case Report

Masaki Otsuka, MD1; Osamu Yamasaki, MD, PhD2; Tatsuya Kaji, MD2; Tadahiko Shien, MD, PhD3; Keiji Iwatsuki, MD, PhD2
[+] Author Affiliations
1Department of Dermatology, Shizuoka Cancer Center Hospital, Shizuoka, Japan
2Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
3Department of Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
JAMA Dermatol. 2016;152(1):111-113. doi:10.1001/jamadermatol.2015.2507.
Text Size: A A A
Published online

Extract

This case report suggests that the combination of pertuzumab-based targeted therapy with taxane chemotherapy may develop into a new treatment option for patients with HER2-positive metastatic cutaneous apocrine carcinoma.

There is no effective treatment for metastatic cutaneous apocrine carcinoma (CAC). In some cases of CAC, human epidermal growth factor receptor 2 (HER2) is overexpressed.1,2 We report the case of a patient with metastatic CAC for whom a combination of the anti-HER2 humanized monoclonal antibodies with taxane chemotherapy was effective.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure 1.
Clinical Features at the Patient

A, A 90 × 50-mm, slightly raised erythematous lesion with lymphadenopathy (100 × 100 mm in size) is present at the right axilla. In-transit or satellite metastases are present around the tumor. B, After 7 cycles of the combination therapy of pertuzumab and trastuzumab with docetaxel, right axillary lesions dramatically decreased. C, After 1 month of surgical treatment.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Biopsy Specimens From the Axillary Area

A, A biopsy specimen revealed that atypical tumor cells proliferated in the skin, forming strands or solid pattern nests in collagen fibers (hematoxylin-eosin, original magnification ×100). B, Immunohistochemical staining for gross cystic disease fluid protein 15 (original magnification ×100) revealed positive tumor cells. C, Immunohistochemical staining for human epidermal growth factor receptor protein 2 (HER2) (original magnification ×100) revealed positive tumor cells.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

425 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

Care at the Close of Life: Evidence and Experience
The Role of Chemotherapy at the End of Life: "When Is Enough, Enough?"

Care at the Close of Life: Evidence and Experience
Chemotherapy and Hormonal Therapy

brightcove.createExperiences();